Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

N/A
8(88.9%)
Phase 2
1(11.1%)
9Total
N/A(8)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT03538236Not ApplicableWithdrawn

Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH

Role: collaborator

NCT03918564Phase 2Unknown

ReShape Vest™ for the Treatment of Obesity (Europe)

Role: lead

NCT03145636Not ApplicableUnknown

The ReNEW Study: Maestro® New Enrollment Post-Approval Study Protocol

Role: lead

NCT02927665Unknown

A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects

Role: lead

NCT00521079Not ApplicableCompleted

EMPOWER Clinical Trial: Vagal Blocking for Obesity Control

Role: lead

NCT03434522Unknown

vBloc Now - Registry

Role: lead

NCT01327976Not ApplicableUnknown

The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity

Role: lead

NCT01061385Not ApplicableCompleted

The Safety and Efficacy of the ReShape Intragastric Balloon in Obese Subjects

Role: lead

NCT01673698Not ApplicableCompleted

A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects

Role: lead

NCT01024465Not ApplicableCompleted

ReShape Intragastric Balloon for the Treatment of Obesity

Role: lead

NCT00555958Not ApplicableUnknown

Vagal Blocking for Obesity Control

Role: lead

All 11 trials loaded